Catalyst Event
Johnson & Johnson (JNJ) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/18/2026, 12:00:00 AM
The U.S. FDA approved Icotyde (icotrokinra) on March 18, 2026, the first targeted oral peptide for treating moderate-to-severe plaque psoriasis. Analysts forecast potential peak annual sales of over $5 billion forecasted. This major approval is expected to have a high market impact.
Korean Translation
2026년 3월 18일, 미국 FDA는 중등도-중증 판상 건선 치료를 위한 최초의 경구용 펩타이드 약물인 아이코타이드(이코트로킨라)를 승인함. 분석가들은 연간 최대 매출이 50억 달러를 넘을 것으로 전망됨. 이 주요 승인은 높은 시장 영향력을 미칠 것으로 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision on LEQEMBI IQLIK (subcutaneous) for treatment initiation is scheduled. The FDA granted Priority Review for this supplemental Biologics License Application, with a PDUFA action date of May 24, 2026, which is expected. This event is expected to have a high price impact due to the significant market potential of the new delivery method.
5/24/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release on May 6, 2026, scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Q1 2026 earnings release is scheduled. Impact is estimated to be low as it is a routine quarterly announcement.
5/5/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is expected to release its Q1 2026 earnings results on or around April 30, 2026, before the market opens. High impact expected as earnings releases often drive price movements exceeding 10%, scheduled.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release is scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva announced it will release its financial results for the first quarter of 2026 on April 29, 2026, scheduled. Low price impact expected for this routine announcement.
4/29/2026, 12:00:00 AM